Large-scale prediction and testing of drug activity on side-effect targets

Nature

Volumn 486, Issue 7403, 2012, Pages 361-367

  Lounkine, Eugen ^a   Keiser, Michael J ^b,c   Whitebread, Steven ^a   Mikhailov, Dmitri ^a   Hamon, Jacques ^d   Jenkins, Jeremy L ^a   Lavan, Paul ^d   Weber, Eckhard ^d   Doak, Allison K ^c   Côté, Serge ^d   Shoichet, Brian K ^c   Urban, Laszlo ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b SeaChange Pharmaceuticals Inc   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALOSETRON; APRINDINE; ARIPIPRAZOLE; CHLORHEXIDINE; CHLOROTRIANISENE; CITALOPRAM; CLEMASTINE; CYCLOBENZAPRINE; CYCLOOXYGENASE 1; DESIPRAMINE; DIPHENHYDRAMINE; DYCLONINE; FASUDIL; FLUSPIRILENE; FLUTAMIDE; HALOPERIDOL; INDOMETACIN; LOXAPINE; METHYLPREDNISOLONE; OXYCODONE; PRENYLAMINE; RANITIDINE; RIFAXIMIN; RITODRINE; SERTRALINE; SIBUTRAMINE; TEGASEROD; TERFENADINE; UNINDEXED DRUG;

BLOOD; DATABASE; DRUG; EMPIRICAL ANALYSIS; ENZYME ACTIVITY; EXPERIMENTAL STUDY; INHIBITION; PROTEIN;

ABDOMINAL PAIN; ARTICLE; ATAXIA; BINDING AFFINITY; CALCULATION; CONSTIPATION; DATA BASE; DEPRESSION; DRUG ACTIVITY; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG TARGETING; ENZYME INHIBITION; HUMAN; HYPERHIDROSIS; MATHEMATICAL MODEL; PREDICTION; PRIORITY JOURNAL; RASH; RISK REDUCTION; SEDATION; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; TACHYCARDIA; THROMBOCYTE AGGREGATION; TREMOR;

BLOOD PLATELETS; CHLOROTRIANISENE; CYCLOOXYGENASE 1; CYCLOOXYGENASE INHIBITORS; DATABASES, FACTUAL; DRUG EVALUATION, PRECLINICAL; ESTROGENS, NON-STEROIDAL; FORECASTING; HUMANS; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; PHARMACEUTICAL PREPARATIONS; PLATELET AGGREGATION; REPRODUCIBILITY OF RESULTS; SUBSTRATE SPECIFICITY; TOXICITY TESTS;

EID: 84862510972     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature11159     Document Type: Article

References (53)

1. Giacomini, K. M. et al. When good drugs go bad. Nature 446, 975-977 (2007). (Pubitemid 46676037)
2. Arrowsmith, J. Trial watch: phase III and submission failures: 2007-2010. Nature Rev. Drug Discov. 10, 87 (2011).
3. Arrowsmith, J. Trial watch: phase II failures: 2008-2010. Nature Rev. Drug Discov. 10, 328-329 (2011).
4. Boyer, S. The use of computer models in pharmaceutical safety evaluation. Altern. Lab. Anim. 37, 467-475 (2009).
5. Wong, D., Wang, M., Cheng, Y. & Fitzgerald, G. A. Cardiovascular hazard and nonsteroidal anti-inflammatory drugs. Curr. Opin. Pharmacol. 5, 204-210 (2005). (Pubitemid 40378754)
6. Antunes, A. M. M. et al. Protein adducts as prospective biomarkers of nevirapine toxicity. Chem. Res. Toxicol. 23, 1714-1725 (2010).
7. Rothman, R. B. et al. Evidence for possible involvement of 5-HT2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 102, 2836-2841 (2000).
8. Roy, M., Dumaine, R. & Brown, A. M. HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine. Circulation 94, 817-823 (1996). (Pubitemid 26289240)
9. Curran, M. E. et al. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 80, 795-803 (1995).
10. Ji, Z. L. et al. Drug Adverse Reaction Target Database (DART): proteins related to adverse drug reactions. Drug Saf. 26, 685-690 (2003). (Pubitemid 36976130)
11. Kuhn, M., Campillos, M., Letunic, I., Jensen, L. J. & Bork, P. A side effect resource to capture phenotypic effects of drugs. Mol. Syst. Biol. 6, 343 (2010).
12. Matthews, E. J. & Frid, A. A. Prediction of drug-related cardiac adverse effects in humans-A: Creation of a database of effects and identification of factors affecting their occurrence. Regul. Toxicol. Pharmacol. 56, 247-275 (2010).
13. Yang, X. et al. Kinase inhibition-related adverse events predicted from in vitro kinome and clinical trial data. J. Biomed. Inform. 43, 376-384 (2010).
14. Hopkins,A. L. Network pharmacology: the next paradigmin drug discovery. Nature Chem. Biol. 4, 682-690 (2008).
15. Zhang, J.-X. et al. DITOP: drug-induced toxicity related protein database. Bioinformatics 23, 1710-1712 (2007). (Pubitemid 47244467)
16. Yang, L., Luo, H., Chen, J., Xing, Q. & He, L. SePreSA: a server for the prediction of populations susceptible to serious adverse drug reactions implementing the methodology of a chemical-protein interactome. Nucleic Acids Res. 37, W406-W412 (2009).
17. Lee, S., Lee, K. H., Song, M. & Lee, D. Building the process-drug-side effect network to discover the relationship between biological processes and side effects. BMC Bioinformatics 12 (suppl. 2), S2 (2011).
18. Schreiber, G. & Keating, A. E. Protein binding specificity versus promiscuity. Curr. Opin. Struct. Biol. 21, 50-61 (2011).
19. Oprea, T. I. et al. Associating drugs, targets and clinical outcomes into an integrated network affords a new platform for computer-aided drug repurposing. Mol. Inform. 30, 100-111 (2011).
20. Paolini, G. V., Shapland, R. H. B., vanHoorn,W. P.,Mason, J. S.&Hopkins, A. L. Global mapping of pharmacological space. Nature Biotechnol. 24, 805-815 (2006). (Pubitemid 44086621)
21. Scheiber, J. et al.Mapping adverse drug reactions in chemical space. J.Med. Chem. 52, 3103-3107 (2009).
22. Bender, A. et al. Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure. ChemMedChem 2, 861-873 (2007).
23. Campillos, M., Kuhn, M., Gavin, A.-C., Jensen, L. J. & Bork, P. Drug target identification using side-effect similarity. Science 321, 263-266 (2008). (Pubitemid 351989100)
24. Tatonetti, N. P. et al. Detecting drug interactions from adverse-event reports: interaction between paroxetine and pravastatin increases blood glucose levels. Clin. Pharmacol. Ther. 90, 133-142 (2011).
25. Keiser, M. J. et al. Predicting new molecular targets for known drugs. Nature 462, 175-181 (2009).
26. Keiser, M. J. et al. Relating protein pharmacology by ligand chemistry. Nature Biotechnol. 25, 197-206 (2007). (Pubitemid 46227119)
27. Hert, J., Keiser, M. J., Irwin, J. J., Oprea, T. I. & Shoichet, B. K. Quantifying the relationships among drug classes. J. Chem. Inf. Model. 48, 755-765 (2008). (Pubitemid 351757743)
28. Azzaoui, K. et al. Modeling promiscuity based on in vitro safety pharmacology profiling data. ChemMedChem 2, 874-880 (2007).
29. Gaulton, A. et al. ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res. 40, D1100-D1107 10.1093/nar/gkr777 (2012).
30. Laggner, C. et al. Chemical informatics and target identification in a zebrafish phenotypic screen. Nature Chem. Biol. 8, 144-146 (2012).
31. Shelley, J. C. et al. Epik: a software program for pKa prediction and protonation state generation for drug-like molecules. J. Comput. Aided Mol. Des. 21, 681-691 (2007).
32. Muchmore, S.W. et al.Application of belief theory to similarity data fusion for use in analog searching and lead hopping. J. Chem. Inf. Model. 48, 941-948 (2008).
33. Yldrm, M. A., Goh, K.-I., Cusick, M. E., Barabási, A.-L. & Vidal, M. Drug-target network. Nature Biotechnol. 25, 1119-1126 (2007). (Pubitemid 47538114)
34. Marshall, V.&Grosset, D. G. Role of dopamine transporter imaging in the diagnosis of atypical tremor disorders. Mov. Disord. 18 (suppl. 7), S22-S27 (2003). (Pubitemid 37336924)
35. Kuo, C. C., Huang, R. C. & Lou, B. S. Inhibition of Na1 current by diphenhydramine and other diphenyl compounds: molecular determinants of selective binding to the inactivated channels. Mol. Pharmacol. 57, 135-143 (2000).
36. Schoen, R. T. & Vender, R. J. Mechanisms of nonsteroidal anti-inflammatory druginduced gastric damage. Am. J. Med. 86, 449-458 (1989). (Pubitemid 19103913)
37. Kong, S. X., Hatoum, H. T., Zhao, S. Z., Agrawal, N. M. & Geis, S. G. Prevalence and cost of hospitalization for gastrointestinal complications related to peptic ulcers with bleeding or perforation: comparison of two national databases. Am. J. Manag. Care 4, 399-409 (1998). (Pubitemid 28350796)
38. G., Perrone, M., Scilimati, A., Simone, L. & Vitale, P. Selective COX-1 inhibition: A therapeutic target to be reconsidered. Curr. Med. Chem. 17, 3769-3805 (2010).
39. Akarasereenont, P., Tripatara, P., Chotewuttakorn, S., Palo, T. & Thaworn, A. The effects of estrone, estradiol and estriol on platelet aggregation induced by adrenaline and adenosine diphosphate. Platelets 17, 441-447 (2006). (Pubitemid 44665566)
40. Norris, L. A.&Bonnar, J. Effect of oestrogen dose on whole blood platelet activation in women taking new low dose oral contraceptives. Thromb. Haemost. 72, 926-930 (1994).
41. Leeson, P. D. & Springthorpe, B. The influence of drug-like concepts on decisionmaking in medicinal chemistry. Nature Rev. Drug Discov. 6, 881-890 (2007). (Pubitemid 350042396)
42. Peters, J.-U., Schnider, P., Mattei, P. & Kansy, M. Pharmacological promiscuity: dependence on compound properties and target specificity in a set of recent Roche compounds. ChemMedChem 4, 680-686 (2009).
43. Cosgrove, B. D. et al. Cytokine-associated drug toxicity in human hepatocytes is associated with signaling network dysregulation. Mol. Biosyst. 6, 1195-1206 (2010).
44. Mestres, J., Gregori-Puigjané, E., Valverde, S. & Solé, R. V. Data completeness-the Achilles heel of drug-target networks. Nature Biotechnol. 26, 983-984 (2008).
45. Mestres, J., Gregori-Puigjané, E., Valverde, S. & Solé, R. V. The topology of drugtarget interaction networks: implicit dependence on drug properties and target families. Mol. Biosyst. 5, 1051-1057 (2009).
46. Rogers, D.& Hahn, M. Extended-connectivity fingerprints. J. Chem. Inf. Model. 50, 742-754 (2010).
47. James, C., Weininger, D. & Delany, J. Daylight Theory Manual-Daylight 4.91 (Daylight Chemical Information Systems, 2005).
48. Wishart, D. S. et al. DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 36, D901-D906 (2008). (Pubitemid 351149842)
49. Stein, S., Heller, S. & Tchekhovski, D. An open standard for chemical structure representation-the IUPAC chemical identifier. Nimes Int. Chem. Inf. Conf. Proc. 143, 131-143 (2003).
50. The UniProt Consortium. Ongoing and future developments at the Universal Protein Resource. Nucleic Acids Res. 39, D214-D219 (2010).
51. Altschul, S. F. et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 25, 3389-3402 (1997). (Pubitemid 27359211)
52. Brown, E. G., Wood, L. & Wood, S. The medical dictionary for regulatory activities (MedDRA). Drug Saf. 20, 109-117 (1999). (Pubitemid 29101275)
53. Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. B 57, 289-300 (1995).